BiotechTube
Corium

Corium

Grand Rapids, United States· Est.
corium.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $75M

Overview

Corium, founded in 1997 and headquartered in Grand Rapids, USA, is a private, commercial-stage biopharmaceutical company with a core focus on neuroscience. The company has transitioned from its historical roots in drug delivery and generics to a specialized neuroscience player, currently marketing products like AZSTARYS for ADHD. Backed by investment firm B-Flexion, Corium is led by a seasoned executive team with extensive experience in pharmaceutical turnarounds, product launches, and business development, positioning it to grow within the competitive CNS market.

NeurosciencePsychiatryNeurology

Technology Platform

Legacy expertise in advanced drug delivery systems (e.g., transdermal, prodrug oral formulations) applied to neuroscience therapeutics.

Funding History

2
Total raised:$75M
Debt$75M
Series AUndisclosed

Opportunities

The large and growing neuroscience market, particularly in ADHD, offers a significant commercial opportunity for AZSTARYS.
The leadership team's proven track record in business development and company transformation provides a clear pathway to acquire and integrate additional assets, diversifying the portfolio and fueling growth.

Risk Factors

High dependence on the commercial success of a single product, AZSTARYS, in a competitive market.
The company's growth-by-acquisition strategy carries inherent integration and execution risks.
The neuroscience R&D sector is characterized by high clinical failure rates and regulatory complexity.

Competitive Landscape

Corium operates in highly competitive therapeutic areas. In ADHD, AZSTARYS competes with numerous other stimulant and non-stimulant medications from large pharmaceutical companies. In Alzheimer's (with its discontinued product), the landscape includes both established symptomatic treatments and emerging disease-modifying therapies. Corium's competitive edge relies on effective commercialization, product differentiation, and strategic portfolio expansion.

More companies in United States →